PubRank

Zakaria Rachid

Author PubWeight™ 9.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 "Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. Prostate 2012 0.82
2 Molecular analysis of the in vivo metabolism and biodistribution of metabolically and non-metabolically activated combi-molecules of the triazene class. Drug Metab Lett 2009 0.82
3 Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J Med Chem 2003 0.82
4 Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. Breast Cancer Res Treat 2011 0.81
5 Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency. Biochem Pharmacol 2005 0.81
6 The combi-targeting concept: evidence for the formation of a novel inhibitor in vivo. Anticancer Drugs 2006 0.79
7 MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1. Mol Cancer Res 2011 0.79
8 Multiple mechanisms of action of ZR2002 in human breast cancer cells: a novel combi-molecule designed to block signaling mediated by the ERB family of oncogenes and to damage genomic DNA. Int J Cancer 2004 0.79
9 Synthesis of water soluble bis-triazenoquinazolines: an unusual predicted mode of binding to the epidermal growth factor receptor tyrosine kinase. Chem Biol Drug Des 2008 0.79
10 The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries. J Signal Transduct 2012 0.78
11 Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias. Leuk Res 2005 0.78
12 Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia. Mol Cancer Ther 2008 0.77
13 [Combi-molecules: a global approach towards better chemoselectivity and chemosensitivity]. Bull Cancer 2004 0.77
14 Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl. Leuk Res 2005 0.77
15 ZRX1, the first EGFR inhibitor-capecitabine based combi-molecule, requires carboxylesterase-mediated hydrolysis for optimal activity. Invest New Drugs 2013 0.76
16 Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Invest New Drugs 2010 0.75
17 A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity. J Pharm Biomed Anal 2011 0.75
18 In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-molecule. Drug Metab Lett 2011 0.75
19 Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile. Chem Biol Drug Des 2014 0.75
20 Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Anticancer Drugs 2009 0.75